Consolidated Revenue Growth
Total revenue grew more than 6% year-over-year in Q4 2025 and more than 5% for the full year 2025, demonstrating top-line growth across all three divisions.
Inpatient Rehabilitation Outperformance
Inpatient rehab revenue increased over 15% year-over-year to $339.2M; adjusted EBITDA rose 11% to $69.2M. Revenue per patient day increased over 6%, average daily census grew nearly 10%, occupancy improved to 82% (same-store occupancy 86%).
Critical Illness Recovery Stability
Critical illness recovery hospitals delivered nearly 5% revenue growth to $629.7M and adjusted EBITDA growth of 5% to $66.4M. Adjusted EBITDA margin remained steady at 10.5%, occupancy was stable at 67% and admissions rose 3%.
Development and Bed Growth Pipeline
Added 150 beds in Q4 and 212 beds in full-year 2025 (202 beds from new hospitals/units and 10 from expansion). Company expects to add 399 beds across 2026–2027 (including 166 already added in 2026), with multiple joint-venture hospital openings underway.
Full-Year EPS Improvement
Earnings per common share from continuing operations increased to $1.16 for the full year 2025 from $0.51 in the prior year. Adjusted EPS from continuing operations rose to $1.00 from $0.94 (up ~6.4%).
2026 Financial Outlook
Management issued 2026 guidance targeting revenue of $5.6B–$5.8B, adjusted EBITDA of $520M–$540M, fully diluted EPS of $1.22–$1.32, and capital expenditures of $200M–$220M, signaling expected growth and improved profitability.
Labor and Operational Progress
Agency costs have stabilized with staffing mix about 70% full-time / 15% PRN / 15% agency; labor-related margin running just above 56%, improving cost predictability versus prior years.
Shareholder Distribution
Board approved a cash dividend of $0.0625 per share payable 03/12/2026, showing continued capital return to shareholders.